- MindMed ( NASDAQ: MNMD ) has dosed the first patient in a phase 2b trial examining a pharmaceutically optimized form of LSD for the treatment of general anxiety disorder .
- In the trial of MM-120 that plans to enroll 200, participants will receive a single dose of up to 200 µg of the drug or placebo. The primary goal is to determine the reduction in anxiety four weeks after administration across the five treatment arms.
- Results from a phase 2a study released in May showed p romise for MM0-120 in anxiety .
- MindMed ( MNMD ) shares spiked briefly last week after a newspaper report of a young investor taking an activist stake .
For further details see:
MindMed doses first patient in mid-stage trial of LSD candidate for anxiety